Mannkind

NEW YORK (AVAFIN) -- During the last trading session, a new 90-day call record for traded contracts was established. There were 3.7 calls traded for every put contract yielding a 0.27 put/call ratio.

View Options Trading Activities

The ratio skew implies that investors are hedging their positions in anticipation of a stock move. Today's unusual volume activity confirms that traders are re-balancing their portfolios.

Safety concerns linking Exubera use to lung cancer in former smokers prompted diabetes experts such as Novo Nordisk and Eli Lilly to discontinue their inhaled insulin products. Additionaly, Afrezza's expected launch delay will push potential profitability out even further and worsen the company's cash burn. If MannKind is not able to establish a partnership before Afrezza's approval, current shareholders will be at risk of additional dilution.

Shares of MannKind edged down $0.20 (3.18%) to $6.25. The price of the stock ranged between a low of $5.93 and $6.70 respectively. The trading volume of 8M is above the 90 day average volume of 7M shares. MNKD is trading above the 50 day moving average. The stock's 52 week low is $1.82 and 52 week high is $8.06. Performance indicators show that the stock has lost -5.69% within the last month.

http://www.avafin.com/articles/1024294.html